Abstract
The Government of Bangladesh has offered COVID-19 vaccines at no cost; however, sustaining this free vaccination program for a large population poses significant challenges. Assessing willingness to pay (WTP) is essential for understanding potential pricing strategies, subsidy requirements, and vaccine demand. This study aimed to estimate the prevalence of WTP for COVID-19 vaccines and identify its influencing factors to support program sustainability. Using a cross-sectional design, data were collected from 1,497 respondents through online, and face-to-face interviews and multiple logistic regression was employed to analyze the correlates of WTP. Results showed that 50.9% of participants were willing to pay, with an average WTP of 754.55 BDT (US$8.93) and a median of 300 BDT (US$3.55). WTP was significantly higher among individuals with graduate (aOR=2.2, P=0.007) or Masters & MPhil/PhD education (aOR=2, P=0.030), higher family income (aOR=1, P=0.039), and those with more excellent knowledge about the vaccine (aOR=1.1, P=0.003), positive behavioral practices (aOR=1.1, P<0.001), stronger subjective norms (aOR=1.2, P=0.009), higher anticipated regret (aOR=1.2, P=0.005), and perceived benefits (aOR=1.1, P=0.029). Conversely, WTP was lower among participants with negative attitudes toward vaccines (aOR=0.9, P<0.001) and high behavioral control (aOR=0.9, P=0.006). With nearly half of respondents unwilling to pay, the study highlights the need to improve vaccine-related knowledge, promote positive behaviors, reduce vaccine hesitancy, and enhance income-based affordability to increase WTP. Health promotion efforts should focus on disseminating vaccine knowledge and addressing negative perceptions. Additionally, a subsidized program for low-income groups could help mitigate financial barriers and promote equitable vaccine access.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was taken from the Bangladesh Medical Research Council-BMRC (Registration No. 39131012021).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes